Romiplostim.
In August 2008, romiplostim (Nplate; Amgen), a thrombopoietin receptor agonist, was approved by the US FDA for the treatment of thrombocytopaenia in patients with chronic immune thrombocytopaenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Cines
Douglas B
DB
Douglas B. Cines is in the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. dcines@mail.med.upenn.edu
Yasothan
Uma
U
Kirkpatrick
Peter
P
D002352:Carrier Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D011961:Receptors, Fc / Q000008:administration & dosage / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists; D011993:Recombinant Fusion Proteins; D013156:Splenectomy; D013921:Thrombocytopenia / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D013926:Thrombopoietin; D014481:United States; D014486:United States Food and Drug Administration
D002352:Carrier Proteins; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; C082218:MPL protein, human; D013926:Thrombopoietin; C488777:romiplostim